Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-607-8 | CAS number: 97-77-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 980
Materials and methods
- Objective of study:
- absorption
- distribution
- excretion
- metabolism
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- Version / remarks:
- adopted in 2010
- Principles of method if other than guideline:
- 35S disulfiram (DSF), 7 mg/kg bw, was administered as a single dose to rats both orally (p.o.) or intraperitoneally (i.p.).
- GLP compliance:
- not specified
Test material
- Reference substance name:
- Disulfiram
- EC Number:
- 202-607-8
- EC Name:
- Disulfiram
- Cas Number:
- 97-77-8
- Molecular formula:
- C10H20N2S4
- IUPAC Name:
- disulfiram
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- 35S-disulfiram
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Madison, Wisc., USA
- Age at study initiation: young adult
- Weight at study initiation: 150 - 250 g
- Fasting period before study: 24 h prior to drug administration and until 4 h after drug administration
- Housing: groups of five in stainless steel wire-bottomed cages
- Individual metabolism cages: yes
- Diet: Purina Chow, ad libitum
- Water: tap water, ad libitum
ENVIRONMENTAL CONDITIONS
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- other: both, orally or i.p.
- Vehicle:
- other: The 35S-disulfiram was solubilized in polysorbate 80 and suspended in 0.5% methyl cellulose
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: 35S-DSF was solubilized in polysorbate 80 and suspended in 0.5% methyl cellulose.
- Duration and frequency of treatment / exposure:
- single dose
Doses / concentrations
- Dose / conc.:
- 7 mg/kg bw (total dose)
- Remarks:
- either i.p. or p.o.
- No. of animals per sex per dose / concentration:
- 3 animals per timepoint
- Control animals:
- no
- Positive control reference chemical:
- No
- Details on dosing and sampling:
- Tissue analysis
Rats were given 35S-DSF in a dose of 7 mg/kg bw either i.p. or p.o., and then sacrificed by decapitation at 0.5, 2, 4, 6, 12, 24, and 48 hr following drug dosing. Exsanguinated blood was collected in citrate solution to prevent clotting. Tissue samples were removed, rinsed, blotted dry, und weighed. Tissues analyzed were liver, kidney, muscle, spleen, lung, stomach, testes, pancreas, thyroid, adrenals, brain, heart, skin, intestinal tract, and adipose layer. Three animals were used at each time period studied for each route of 35S-DSF administration. Approximately 100-300 mg of tissue sample was digested in a mixture of 0.8 mL of 70% perchloric acid and 0.4 mL of 30% hydrogen peroxide at 70ºC for 1 hr. Samples were allowed to cool to room temperature and then 20 mL of a triton X-100 scintillation cocktail was added. Samples were counted on a Beckman Scintillation counter (Model 1650). Appropriate corrections for quenching were made.
Gastrointestinal Tract Analysis
In a separate study 35S-DSF was given in a dose of 7 mg/kg bw either i.p. or p.o. and the animals then were immediately placed into stainless steel metabolism cages. The rats then were sacrificed by decapitation at 0.5, 1, 2, 4, 6, 12, 24, and 48 hr following drug administration. The intestinal tract plus contents (minus stomach) was removed and homogenized in a polytron homogenizer with 24 mL of 0.01 g EDTA/1% sodium chloride buffer, pH 8,5, and 6 mL of dimethyl sulfoxide (DMSO).
Breath, Urine, and Faeces Analysis
For the simultaneous collection of breath, urine, and faeces, animals were housed in a modified Roth-Delmar metabolism cage. The chamber was continuously vented with CO2-free air at a constant rate. Carbon disulfide in the expired air was collected by bubbling the air through a double trapping system containing a modified Viles reagent. Nonradioactive CS2 was determined spectrophotometrically. Radioactive CS2, was determined by taking 1 mL aliquots of the trapping solution and placing it in 15 mL of the triton X-100 scintillation cocktail and counted. Urine and faeces were collected in the metabolism cages separately. Aliquots of urine (50-100 mL) and faeces (200-300 mg) were treated similarly to the tissue samples and total radioactivity determined.
Disulfiram Metabolite Studies
Tissue analysis.
The time period at which the greatest radioactivity was found for each route of 35S-DSF administration was determined. One hour after i.p. and 5 hr after p.o. administration were the time periods selected. The 35S-DSF then was administered, and the rats sacrificed by decapitation 1 and 5 hr after dosing. Exsanguinated blood was collected in a citrate solution to prevent clotting. Tissues were excised and 35S-DSF metabolites determined as described previously.
Urine analysis.
A group of rats were given 35S-DSF i.p. and p.o., and immediately placed in stainless steel cages. Urine was collected for 48 hr and 35S-DSF and 35S metabolites determined.
Results and discussion
Main ADME resultsopen allclose all
- Type:
- absorption
- Results:
- The 35S DSF was rapidly absorbed (at least 80%) by either route.
- Type:
- distribution
- Results:
- Kidney, pancreas, liver, and the gastrointestinal tract exhibited the greatest uptake of radioactivity, while the least was found in brain. Preferential tissue uptake was similar with both routes of administration.
- Type:
- metabolism
- Results:
- The 35S-DSF was rapidly metabolized to the 35S-diethyldithiocarbamate-glucuronide and 35S inorganic sulfate.
- Type:
- excretion
- Results:
- 7% of the dose was excreted in the feces. Approximately 12% of the dose was eliminated by the breath as CS2. Most of the radioactivity is eliminated after 48 hr.
- Type:
- other:
- Results:
- Approximately 93% of the radioactivity was accounted for 48 hr after p.o. or i.p. 35S administration.
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- 48 h after i.p injection of the test material, 93.21% of the radioactivity could be recovered. 6.73% of the radioactivity were excretet via feces and 5.25% were found in the gastrointestinal tract (+ contents). 66.1% were found in the urine, 12.64% in the exhaled air and 2.47% in tissues. Therefore, the absorption was at least 81.2% (Table 3).
48 h after oral administration of the test material, 92.36% of the radioactivity were recovered. 6.52% of the radioactivity were excretet via feces and 5.10% were found in the gastrointestinal tract (+ contents). 66.82% were found in the urine, 11.00% in the exhaled air and 2.91% in tissues. Therefore, the absorption was at least 80.7% (Table 4). - Details on distribution in tissues:
- Radioactivity in the various tissues investigated peaked between 0.5 and 1 hour after i.p. (Table 1) and between 4 and 6 hr following p.o.35S-DSF administration (Table 2). Greatest uptake after i.p. dosing was found in kidney > pancreas > liver > largo intestine > small intestine > fat, while tissues exhibiting the least uptake were brain < muscle < heart < adrenal gland < testes. Generally, the p.o. route led to an uptake pattern similar that observed after i.p.35S-DSF. Only in the stomach was uptake greater after p.o.35S-DSF as compared to the i.p. route, which is not surprising since the stomach may not have been completely emptied. Furthermore, if uptake into tissues was compared either 1 hr after i.p. or p.o35S-DSF, or 6 hr after i.p. or p.o.35S-DSF, the rank order For each tissue uptake was similar. The dpm/g for each tissue studied after p.o.35S-DSF was found to be approximately 1/2 that observed after i.p. administration, reflecting greater bioavailability after i.p. dosing. After 48 hrs, approximately 93% of the dose of35S-DSF administered could be accounted for regardless of the route of administration.
Total tissue radioactivity 0.5 hr after i.p. 35S-DSF corresponded to approximately 23% of the total dpm administered, whereas 6 hr after p.o. 35S-DSF the tissues accounted for only about 10% of the radioactivity. After p.o. 35S-DSF, radioactivity in the tissues gradually increased, reflecting stomach emptying and drug absorption, and then declined at the same rate as that observed after i.p. administration.
- Details on excretion:
- Approximately 12% of the dose was eliminated as CS2. After either i.p. or p.o. dosing, radioactive CS2in breath was found within 2 hr. No urine was excreted for the first 4 hr after each route of administration.
After i.p. administration, total radioactivity in the tissues as the percent of35S-DSF administered declined in a biexponential manner, After p.o.35S-DSF, tissue radioactivity gradually increased peaking within 6 hr, The plasma decline was similar after both routes of administration. Radioactivity found in urine during the first 6 hr was less after p.o. than after
i.p. administration. This is due to the i.p. route being absorbed more rapidly und metabolized to water soluble metabolites that are subsequently excreted in the urine.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- One and 6 hr after i.p. and p.o. dosing respectively, the greatest amount of35S in the tissues was due primarily to35S-DDTC-glucuronide and35S inorganic sulfate. These water soluble metabolites constituted approximately 80% of the radioactivity regardless of the route of administration. An exception to this was the pancreas and fat in which only approximately 19% of the radioactivity was due to the glucuronide and inorganic sulfate after i.p. dosing, while after p.o. administration approximately 50% was due to these water soluble metabolites. Also, more parent35S-DSF was found in fat tissue after i.p. than after oral administration. Greater amounts of35S-DSF also were found in the pancreas and fat after i.p. than after p.o. 35S-DSF.
lncreased35S in the kidney, liver, and intestinal tract appears to be due to water soluble metabolites. Even though the testes, adrenal gland, heart, muscle, and brain have a high blood flow, the rapid metabolism of 35S-DSF precludes the uptake of polar metabolites into tissue.
Any other information on results incl. tables
Table 1. Distribution of35S after i-p.35S-Disulfiram (% of35S-Disulfiram administered)
Tissue |
Time (hr) after administration |
|||||||
0.5 |
1.0 |
2.0 |
4.0 |
6.0 |
12.0 |
24.0 |
48.0 |
|
Thyroid |
0.0024 |
0.0028 |
0.0022 |
0.0022 |
0.0019 |
0.0018 |
0.0014 |
0.0017 |
Adrenals |
0.0156 |
0.0054 |
0.0060 |
0.0041 |
0.0041 |
0.0025 |
0.0020 |
0.0014 |
Stomach |
1.2259 |
0.3688 |
0.2521 |
0.2738 |
0.2841 |
0.3237 |
0.1826 |
0.1436 |
Muscle* |
8.2965 |
4.5871 |
4.1079 |
3.7431 |
3.3109 |
2.1308 |
1.4491 |
1.0880 |
Brain |
0.0627 |
0.0459 |
0.0459 |
0.0437 |
0.0442 |
0.0296 |
0.0222 |
0.0190 |
Liver |
6.4349 |
2.8972 |
2.2768 |
2.3615 |
1.6110 |
1.0060 |
0.5057 |
0.3260 |
Testes |
0.5389 |
0.4996 |
0.3162 |
0.3095 |
0.2646 |
0.1765 |
0.0972 |
0.0693 |
Kidney |
1.6317 |
0.9493 |
0.6855 |
0.6102 |
0.5015 |
0.3160 |
0.1705 |
0.1131 |
Lung |
0.4634 |
0.3053 |
0.3542 |
0.2506 |
0.2056 |
0.1227 |
0.0759 |
0.0704 |
Spleen |
0.3851 |
0.1894 |
0.0979 |
0.0726 |
0.0606 |
0.0456 |
0.0284 |
0.0161 |
Heart |
0.0972 |
0.0744 |
0.0637 |
0.0564 |
0.0479 |
0.0320 |
0.0179 |
0.0144 |
Blood** |
3.8653 |
2.9395 |
3.5082 |
3.3053 |
2.7393 |
1.5999 |
0.9502 |
0.6005 |
Total |
23.0296 |
13.0363 |
11.7166 |
11.0330 |
9.0724 |
5.7771 |
3.503 |
2.4658 |
Rats were given 7 mg/kg35S-disulfiram. i.p. and sacrified at the times indicated. Tissues were excised and radioactivity determined. Each value is the average of three rats.
* based on 40% of body weight
** based on 7% of body weight
Table 2: Distribution of35S after p.o.35S-Disulfiram (% of35S administered)
Tissue |
Time (hr) after administration |
|||||||
0.5 |
1.0 |
2.0 |
4.0 |
6.0 |
12.0 |
24.0 |
48.0 |
|
Thyroid |
0.0005 |
0.0005 |
0.0011 |
0.0015 |
0.0013 |
0.0010 |
0.0007 |
- |
Adrenals |
0.0008 |
0.0014 |
0.0029 |
0.0035 |
0.0017 |
0.0015 |
0.0010 |
0.0015 |
Pancreas |
0.0537 |
0.0480 |
0.0465 |
0.056 1 |
0.1214 |
0.0463 |
0.0384 |
0.0268 |
Stomach |
2.2113 |
0.9214 |
0.9082 |
1.1354 |
0.3621 |
0.2813 |
0.1616 |
0.1446 |
Muscle* |
0.5244 |
1.3940 |
2.2860 |
2.8859 |
3.2715 |
1.8280 |
1.4048 |
1.0915 |
Brain |
0.0058 |
0.0114 |
0.0150 |
0.0273 |
0.0405 |
0.0244 |
0.0251 |
0.0196 |
Liver |
0.9807 |
1.8321 |
1.4673 |
2.2578 |
2.2330 |
0.9998 |
0.6483 |
0.4160 |
Testes |
0.0172 |
0.0696 |
0.0989 |
0.1709 |
0.2614 |
0.1268 |
0.1030 |
0.0739 |
Kidney |
0.2639 |
0.4171 |
0.4626 |
0.6616 |
0.7426 |
0.3501 |
0.1879 |
0.1331 |
Lung |
0.0467 |
3.1392 |
0.1233 |
0.1782 |
0.2264 |
0.0987 |
0.0790 |
0.0539 |
Spleen |
0.0217 |
0.0301 |
0.0291 |
0.0462 |
0.0670 |
0.0401 |
0.0400 |
0.0232 |
Heart |
0.0224 |
0.0224 |
0.0278 |
0.0427 |
0.0562 |
0.0357 |
0.0226 |
0.0154 |
Blood** |
0.8803 |
1.0310 |
1.4400 |
2.0520 |
2.9300 |
1.7698 |
1.2116 |
0.9135 |
Total |
5.0771 |
5.9182 |
6.8963 |
9.5184 |
10.3169 |
5.6038 |
3.9246 |
2.9123 |
Rats were given 7 mg/kg35S-disulfiram. i.p. and sacrified at the times indicated. Tissues were excised and radioactivity determined. Each value is the average of three rats.
* based on 40% of body weight
** based on 7% of body weight
Table 3: Distribution and Excretion of Radioactivity after i.p.35S-Disulfiram (% of35S-Disulfiram administered, mean values)
|
Time (hr) after administration |
||
|
12 |
24 |
48 |
Diverse tissues |
5.78 |
3.5 |
2.47 |
Gastrointestinal tract |
10.38 (5) |
4.74 (5) |
5.25 (4) |
Urine |
32.6 (5) |
48.64 (5) |
66.10 (4) |
Faeces |
- |
- |
6.75 (3) |
Breath |
10.34 (5) |
10.97 (5) |
12.64 (3) |
Total |
|
|
93.21 |
Number of rats in parenthesis
Table 4: Distribution and Excretion of Radioactivity after p.o.35S-Disulfiram (% of35S-Disulfiram administered, mean values)
|
Time (hr) after administration |
||
|
12 |
24 |
48 |
Diverse tissues |
5.60 |
3.92 |
2.91 |
Gastrointestinal tract |
12.30 (5) |
8.86 (5) |
5.10 (4) |
Urine |
45.24 (5) |
59.48 (5) |
66.82 (4) |
Faeces |
- |
- |
6.52 (4) |
Breath |
8.82 (2) |
10.70 (4) |
11.00 (4) |
Total |
|
|
92.36 |
Number of rats in parenthesis
Applicant's summary and conclusion
- Conclusions:
- The studies were conducted similar to guidelines and under GLP conditions. The test substance was excreted mainly via urine and expired air. Kidney, pancreas and liver were the tissues which contained the highest concentration of 14C-test substance residues. The 35S-DSF was rapidly metabolized to the 35S-diethyldithiocarbamate-glucuronide and 35S inorganic sulfate. No bioaccumulation potential was assumed based on the study results, as most of the radioactivity was excreeted after 48 h.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.